Elutia Inc. Share Price

ELUT

US05479K1060

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 16/10/2026 BST			5-day change	1st Jan Change
0.7940 ^USD	+0.66%		-3.54%	+14.62%

10-01	Elutia Reports $8 Million Payment from Boston Scientific	MT
08-17	Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million.	CI

Last Transcript: Elutia Inc.

Elutia Inc., Q2 2026 Earnings Call, Aug 13, 2026

08-13

More transcripts

Analysts' recommendations: Elutia Inc.

18/08/25	Cantor Fitzgerald Adjusts Elutia Price Target to $5 From $7, Maintains Overweight Rating	MT
21/06/24	Lake Street Adjusts Elutia Price Target to $10 From $5, Maintains Buy Rating	MT
20/06/24	Cantor Fitzgerald Adjusts Price Target on Elutia to $11 From $5, Maintains Overweight Rating	MT
14/11/23	Cantor Fitzgerald Cuts Elutia's Price Target to $6 From $8, Keeps Overweight Rating	MT
28/09/23	Lake Street Initiates Elutia at Buy Rating With $3 Price Target	MT

More recommendations

Managers and Directors: Elutia Inc.

Manager	Title	Age	Since
Charles Mills CEO	Chief Executive Officer	54	20/06/2022
Michelle Williams COO	Chief Operating Officer	52	-
Matthew Ferguson DFI	Director of Finance/CFO	58	27/09/2020

Director	Title	Age	Since
Kevin Rakin CHM	Chairman	65	31/10/2015
Charles Mills BRD	Director/Board Member	54	31/10/2015
Brigid Makes BRD	Director/Board Member	70	31/08/2020

More insiders

Elutia Inc. is a commercial-stage company developing proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. Its cardiovascular biomatrix portfolio spans pericardial closure, intracardiac tissue repair, and vascular reconstruction. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. Its cardiovascular products are specifically designed to provide immediate structural support while promoting tissue regeneration, cellular infiltration, and natural integration over time. It is focused on developing NXT-41x, an antibiotic-eluting biomatrix designed to address post-operative infection. The NXT-41x product is designed to provide soft-tissue reinforcement while locally delivering antibiotics locally to inhibit bacterial colonization at the surgical site.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	US$0.7940	+0.66%	86,602
15/10/26	US$0.7888	+7.32%	123,877
14/10/26	US$0.7350	-4.94%	293,262
13/10/26	US$0.7732	-1.75%	36,584
12/10/26	US$0.7870	-4.39%	69,836

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7940USD

Average target price

5.000USD

Spread / Average Target

+529.72%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Elutia Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Elutia Inc.

Company calendar

Market Cap	35.17M 31.26M 28.97M 26.36M 49.74M 3.34B 50.54M 348M 137M 1.74B 132M 129M 5.55B	P/E 2026 *	-1.26x	P/E 2027 *	-1.47x
Enterprise Value	35.17M 31.26M 28.97M 26.36M 49.74M 3.34B 50.54M 348M 137M 1.74B 132M 129M 5.55B	EV / Sales 2026 *	4.69x	EV / Sales 2027 *	8.18x
Free-Float	85.18%	Yield 2026 *	-	Yield 2027 *	-

10-01	Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029	AQ
09-10	Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th	AQ
09-02	Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-19	Cellution Biologics Completes Acquisition of SimpliDerm(R) from Elutia Inc.	AQ
08-18	Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.	AQ

1 day	+0.66%
1 week	-3.54%
Current month	+0.51%
1 month	-6.59%
3 months	-16.42%
6 months	-30.96%
Current year	+14.62%

1 week	0.71	0.81
1 month	0.67	0.9
Current year	0.6	1.38
1 year	0.5	1.38
3 years	0.5	5.24
5 years	0.5	9.01
10 years	0.5	18.2

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/09/26	Charles Mills	Exercice	Founder	63,884	0.1445%
10/09/26	Michelle Williams	Exercice	Founder	29,269	0.0662%
10/09/26	Matthew Ferguson	Exercice	Chief Financial Officer	29,486	0.0667%

Elutia Inc. Share Price

Stocks

ELUT

US05479K1060

Pharmaceuticals

Valuation: Elutia Inc.

Chart: Elutia Inc.

Latest news: Elutia Inc.

Last Transcript: Elutia Inc.

Analysts' recommendations: Elutia Inc.

Press Releases: Elutia Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Elutia Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELUTIA INC.	+0.66%	-3.54%	-10.86%	-40.30%	35.17M
ELI LILLY AND COMPANY	+0.43%	+6.59%	+56.57%	+107.01%	1,120B
JOHNSON & JOHNSON	+0.90%	-2.25%	+32.26%	+67.33%	616B
ABBVIE INC.	+0.71%	+3.24%	+24.33%	+91.20%	504B
ROCHE HOLDING AG	-0.28%	+4.92%	+34.36%	+58.40%	367B
MERCK & CO., INC.	+0.52%	+0.24%	+72.13%	+43.10%	360B
NOVARTIS AG	-0.11%	+3.68%	+19.44%	+46.76%	288B
ASTRAZENECA PLC	-0.98%	+2.39%	-1.99%	+17.41%	258B
AMGEN INC.	-0.35%	+4.25%	+44.74%	+52.51%	234B
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+27.18%	+96.05%	194B
Average	+0.07%	+2.63%	+29.82%	+53.95%	394.09B
Weighted average by Cap.	+0.24%	+3.52%	+39.31%	+74.39%

	2026 *	2027 *
Net sales	7.5M 6.67M 6.18M 5.62M 10.61M 712M 10.78M 74.28M 29.12M 371M 28.15M 27.55M 1.18B	4.3M 3.82M 3.54M 3.22M 6.08M 408M 6.18M 42.58M 16.7M 213M 16.14M 15.79M 679M
Net income	-27.3M -24.27M -22.49M -20.46M -38.62M -2.59B -39.24M -270M -106M -1.35B -102M -100M -4.31B	-23.6M -20.98M -19.44M -17.69M -33.38M -2.24B -33.92M -234M -91.64M -1.17B -88.57M -86.69M -3.73B
Net Debt	-	-